Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026GuruFocus · 5 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 16, 2026
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)Business Wire · Oct 8, 2026
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What HappenedDefense World · Oct 7, 2026
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law FirmPRNewsWire · Sep 30, 2026
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Sep 21, 2026Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.84 | -$0.84 | Beat |
| May 7, 2026 | -$0.82 | -$0.83 | Miss |
| Mar 3, 2026 | -$0.88 | -$0.88 | Beat |
| Nov 14, 2025 | -$0.84 | -$0.90 | Miss |
| Aug 6, 2025 | -$0.66 | -$0.98 | Miss |
| May 14, 2025 | -$0.63 | -$0.67 | Miss |